Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
Sarah Bassiony, Claire N Harrison, Donal P McLornan Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UKCorrespondence: Donal P McLornanDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust,...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6e55eacd587643f6a14e3b28f2c17888 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6e55eacd587643f6a14e3b28f2c17888 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6e55eacd587643f6a14e3b28f2c178882021-12-02T12:02:29ZEvaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date1178-203Xhttps://doaj.org/article/6e55eacd587643f6a14e3b28f2c178882020-09-01T00:00:00Zhttps://www.dovepress.com/evaluating-the-safety-efficacy-and-therapeutic-potential-of-momelotini-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XSarah Bassiony, Claire N Harrison, Donal P McLornan Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UKCorrespondence: Donal P McLornanDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Tower, Great Maze Pond, London, SE1 9RT, UKTel +44 20 7188 2742Email donal.mclornan@nhs.netAbstract: Myelofibrosis is a heterogeneous disorder with regard to both molecular pathogenesis and clinical phenotype, ranging from an initial fairly indolent condition in some through to an aggressive and debilitating scenario with profound constitutional symptoms, cytopenia frequently requiring transfusional support, and massive splenomegaly. Many advances have been made within the therapeutic arena, and an increasing array of novel agents are now available for disease management. Within this review, we focus on the current and predicted role of the JAK inhibitor momelotinib (Sierra Oncology) in myelofibrosis, with an emphasis on clinical trial evaluation, drug efficacyand safety, and discuss the suggested place in the therapeutic paradigm of myelofibrosis in 2020 and beyond.Keywords: myelofibrosis, JAK inhibitors, momelotinibBassiony SHarrison CNMcLornan DPDove Medical Pressarticlemyelofibrosisjak inhibitorsmomelotinibTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 889-901 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
myelofibrosis jak inhibitors momelotinib Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
myelofibrosis jak inhibitors momelotinib Therapeutics. Pharmacology RM1-950 Bassiony S Harrison CN McLornan DP Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| description |
Sarah Bassiony, Claire N Harrison, Donal P McLornan Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UKCorrespondence: Donal P McLornanDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Tower, Great Maze Pond, London, SE1 9RT, UKTel +44 20 7188 2742Email donal.mclornan@nhs.netAbstract: Myelofibrosis is a heterogeneous disorder with regard to both molecular pathogenesis and clinical phenotype, ranging from an initial fairly indolent condition in some through to an aggressive and debilitating scenario with profound constitutional symptoms, cytopenia frequently requiring transfusional support, and massive splenomegaly. Many advances have been made within the therapeutic arena, and an increasing array of novel agents are now available for disease management. Within this review, we focus on the current and predicted role of the JAK inhibitor momelotinib (Sierra Oncology) in myelofibrosis, with an emphasis on clinical trial evaluation, drug efficacyand safety, and discuss the suggested place in the therapeutic paradigm of myelofibrosis in 2020 and beyond.Keywords: myelofibrosis, JAK inhibitors, momelotinib |
| format |
article |
| author |
Bassiony S Harrison CN McLornan DP |
| author_facet |
Bassiony S Harrison CN McLornan DP |
| author_sort |
Bassiony S |
| title |
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| title_short |
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| title_full |
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| title_fullStr |
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| title_full_unstemmed |
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| title_sort |
evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate/high-risk myelofibrosis: evidence to date |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/6e55eacd587643f6a14e3b28f2c17888 |
| work_keys_str_mv |
AT bassionys evaluatingthesafetyefficacyandtherapeuticpotentialofmomelotinibinthetreatmentofintermediatehighriskmyelofibrosisevidencetodate AT harrisoncn evaluatingthesafetyefficacyandtherapeuticpotentialofmomelotinibinthetreatmentofintermediatehighriskmyelofibrosisevidencetodate AT mclornandp evaluatingthesafetyefficacyandtherapeuticpotentialofmomelotinibinthetreatmentofintermediatehighriskmyelofibrosisevidencetodate |
| _version_ |
1718394754221211648 |